Investor Relations
ContraVac is a Virginia corporation developing diagnostic and therapeutic products for reproductive health. The Company initiated operations in 2002. The SpermCheck products have been developed with the funds raised in various Preferred Stock Offerings since September 2004. The lead investor in these Offerings was the Piedmont Angel Network. ContraVac is currently raising investment capital. For more information, please contact the Company's President and CFO, Ed Leary.
In 2009 we will be selling SpermCheck, immunodiagnostic point-of-care sperm tests for use at home or in the clinic. These tests are similar in principle to home pregnancy tests and will be marketed to vasectomized men, couples concerned or curious about their fertility and in the future, men taking oral contraceptives. We estimate the annual global retail markets for the current SpermCheck Products , SpermCheck Vasectomy and SpermCheck Fertility, to be over $300 million. The global retail market for SpermCheck Contraception is estimated at $500 million. Patents licensed to the Company from the University of Virginia provide ContraVac an exclusive U.S. market for immunodiagnostic point-of-care sperm tests utilizing sperm or testes specific antigens. Additional U.S. and international patents have been licensed that protect the biomarkers used in SpermCheck. The SpermCheck products have been developed in collaboration with our manufacturing partner Princeton BioMeditech Corporation (PBM).
ContraVac is currently identifying marketing and distribution partners for the SpermCheck products. For more information, please contact the Company’s President Ed Leary.
